Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 2.39 is in line with its 5-year average of 2.61, around the middle of its 5-year range (0.06–6.47).
As of the fiscal period ended Tuesday, June 30, 2026. 29.15% below its 12-month average of 3.38.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 2.39.
CURRENT RATIO
2.39
CURRENT RATIO AVG TTM
3.38
CURRENT RATIO AVG 3Y
3.81
CURRENT RATIO AVG 5Y
2.61
CURRENT RATIO AVG 10Y
N/A
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-29.15%
CURRENT VS 3Y AVG
-37.23%
CURRENT VS 5Y AVG
-8.31%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.49
median of 700 covered companies
CURRENT VS SECTOR MEDIAN
-31.32%
vs the sector median at left
Market Cap
$116.57M
Current Ratio
2.00
TTM Avg
1.45
3Y Avg
1.62
5Y Avg
1.71
Market Cap
$116.35M
Current Ratio
13.40
TTM Avg
10.04
3Y Avg
7.53
5Y Avg
8.95
Market Cap
$116.84M
Current Ratio
3.36
TTM Avg
3.23
3Y Avg
4.24
5Y Avg
6.08
Market Cap
$117.53M
Current Ratio
6.49
TTM Avg
6.44
3Y Avg
8.52
5Y Avg
8.53
Market Cap
$118.99M
Current Ratio
13.55
TTM Avg
17.30
3Y Avg
10.78
5Y Avg
9.73
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Genelux Corporation (GNLX) | $116.36M | 2.39 | 3.38 | 3.81 | 2.61 |
| Lucid Diagnostics Inc. (LUCD)vs › | $116.31M | 1.33 | 1.19 | 1.50 | 3.26 |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $116.57M | 2.00 | 1.45 | 1.62 | 1.71 |
| Coya Therapeutics, Inc. (COYA)vs › | $116.35M | 13.40 | 10.04 | 7.53 | 8.95 |
| Foghorn Therapeutics Inc. (FHTX)vs › | $116.84M | 3.36 | 3.23 | 4.24 | 6.08 |
| Caribou Biosciences, Inc. (CRBU)vs › | $117.53M | 6.49 | 6.44 | 8.52 | 8.53 |
| MaxCyte, Inc. (MXCT)vs › | $114.08M | 12.26 | 9.59 | 11.55 | 11.23 |
| LENZ Therapeutics, Inc. (LENZ)vs › | $118.99M | 13.55 | 17.30 | 10.78 | 9.73 |
| BGM Group Ltd. (BGM)vs › | $116.34M | 1.25 | 2.31 | 3.27 | 2.89 |
| TuHURA Biosciences, Inc. (HURA)vs › | $121.63M | 0.18 | 2.23 | 2.69 | 2.63 |
Current Ratio
2.39
Quick Ratio
2.39
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 2.39 |
| 2026-03-31 | 3.68 |
| 2025-12-31 | 2.43 |
| 2025-09-30 | 4.20 |
| 2025-06-30 | 4.18 |
| 2025-03-31 | 4.67 |
| 2024-12-31 | 4.57 |
| 2024-09-30 | 6.47 |
| 2024-06-30 | 6.01 |
| 2024-03-31 | 2.72 |
| 2023-12-31 | 3.69 |
| 2023-09-30 | 3.56 |
| 2023-06-30 | 3.64 |
| 2023-03-31 | 1.14 |
| 2022-12-31 | 0.06 |
| 2022-09-30 | 0.13 |
| 2022-06-30 | 0.20 |
| 2022-03-31 | 0.28 |
| 2021-12-31 | 0.26 |
| 2021-09-30 | 0.26 |
| 2021-06-30 | 0.26 |
| 2021-03-31 | 0.67 |
| 2020-12-31 | 0.79 |
| 2020-09-30 | 0.79 |
| 2020-06-30 | 0.79 |
| 2020-03-31 | 0.00 |
